Recommended Pages at ca.us.biz.yahoo.com
AVEO--™s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at EORTC-NCI-AACR Symposium: Financial News - Yahoo! Finance
ca.us.biz.yahoo.com — “AVEO--™s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at EORTC-NCI-AACR Symposium. - CAMBRIDGE, Mass. & BERLIN--(BUSINESS WIRE)-- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO - News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company--™s lead product candidate, tivozanib, a highly ” View full resource at ca.us.biz.yahoo.com
Most Recently Shared on November 19, 2010 at 3:04 pm By:
Kidney Cancer Health Executive
AVEO’s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity http://bit.ly/cP9kKK
Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting: Financial News - Yahoo! Finance
ca.us.biz.yahoo.com — “Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting. - CHICAGO, June 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq:GHDX - News) today announced the first results from its collaboration with Pfizer Oncology to study early-stage renal cell carcinoma prognosis, which demonstrated a strong correlation between gene expression and recurrence risk in this patient population. ” View full resource at ca.us.biz.yahoo.com
Most Recently Shared on June 5, 2010 at 1:36 pm By:
Kidney Cancer Health Executive
Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at Amer... http://bit.ly/b7dspp
ZymoGenetics Announces Upcoming Presentation of Positive IL-21 Phase 2 Results in Metastatic Melanoma at ASCO Meeting: Financial News - Yahoo! Finance
ca.us.biz.yahoo.com — “ZymoGenetics Announces Upcoming Presentation of Positive IL-21 Phase 2 Results in Metastatic Melanoma at ASCO Meeting. - SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN - News) announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation.” View full resource at ca.us.biz.yahoo.com
Most Recently Shared on May 21, 2010 at 8:44 pm By:
Kidney Cancer Health Executive
About Interleukin 21 http://bit.ly/dbDRNa
